Abstract
The preparation of a series of carbamate derivatives of dipeptide nitriles provides cathepsin inhibitors that, according to the P3 residue employed, are reported to selectively inhibit cathepsin S or cathepsin K. The resulting inhibitors are claimed to be useful in the treatment of autoimmune diseases or bone diseases, respectively.